2-(2-fluorophenyl)-5,6,7,8-tetrahydro-4H-[1]benzothieno[2,3-d][1,3]oxazin-4-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-fluorophenyl)-5,6,7,8-tetrahydro-4H-[1]benzothieno[2,3-d][1,3]oxazin-4-one
• 英文别名: 2-(2-fluorophenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d][1,3]oxazin-4-one
• 化学式: C₁₆H₁₂FNO₂S
• 分子量: 301.3
• InChiKey: HDQZJWISFBAGPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  66.9
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS
  申请人：MOLECULAR SKIN THERAPEUTICS, INC.

  公开号：US20210101911A1

  公开（公告）日：2021-04-08

  The present invention provides compounds and pharmaceutical compositions including the compounds for the treatment of a skin disease associated with proteolytic activity of one or more KLK proteases, wherein the compounds are according to formula (I): wherein R is as described herein.

  本发明提供了化合物和包括这些化合物的药物组合物，用于治疗与一个或多个KLK蛋白酶的蛋白水解活性相关的皮肤疾病，其中这些化合物符合以下公式（I）：其中R如本文所述。
• USE OF CONDENSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN DISEASES
  申请人：Arexis AB

  公开号：EP1631295B1

  公开（公告）日：2010-03-03
• Use of heterocyclic compounds as scce inhibitors
  申请人：Linschoten Marcel

  公开号：US20060258651A1

  公开（公告）日：2006-11-16

  The present invention relates to heterocyclic inhibitors of stratum corneum chymotryptic enzyme (SCCE). More particularly, the invention relates to the use of compounds with the formula (I) or (II) for treatment of certain diseases, in particular skin diseases such as pruirtus, as well as cancer such as ovarian cancer.
• US7872052B2
  申请人：——

  公开号：US7872052B2

  公开（公告）日：2011-01-18
• [EN] BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS<br/>[FR] COMPOSÉS DE BENZOXAZINONE UTILISÉS COMME INHIBITEURS DOUBLES DE KLK5/7
  申请人：MOLECULAR SKIN THERAPEUTICS INC

  公开号：WO2021067335A1

  公开（公告）日：2021-04-08

  The present invention provides compounds and pharmaceutical compositions including the compounds for the treatment of a skin disease associated with proteolytic activity of one or more KLK proteases, wherein the compounds are according to formula (I): wherein R is as described herein.